Automate Your Wheel Strategy on MCK
With Tiblio's Option Bot, you can configure your own wheel strategy including MCK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MCK
- Rev/Share 2867.8195
- Book/Share -13.5304
- PB -43.1548
- Debt/Equity -3.5632
- CurrentRatio 0.8993
- ROIC 0.2659
- MktCap 89440066560.0
- FreeCF/Share 44.8163
- PFCF 15.9401
- PE 27.1633
- Debt/Assets 0.0983
- DivYield 0.004
- ROE -1.3273
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MCK | Mizuho | -- | Neutral | -- | $630 | Dec. 4, 2024 |
| Downgrade | MCK | Robert W. Baird | Outperform | Neutral | $603 | $531 | Sept. 24, 2024 |
| Reiterated | MCK | Leerink Partners | -- | Outperform | $670 | $665 | Sept. 5, 2024 |
News
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how McKesson (MCK) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Read More
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why McKesson (MCK) is a Strong Momentum Stock
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
Read More
Is McKesson (MCK) a Buy as Wall Street Analysts Look Optimistic?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson's MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson's strategic execution and long-term positioning, underpinned by record full-year revenues of $359 billion and a 20% year-over-year increase in adjusted earnings per share (to $33.05).
Read More
McKesson To Spin-Off Its Medical-Surgical Solutions Business
Published: May 15, 2025 by: Forbes
Sentiment: Positive
Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses.
Read More
3 Reasons Growth Investors Will Love McKesson (MCK)
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Read More
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
McKesson Corporation (MCK) CFO Britt Vitalone Hosts BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.
Read More
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
McKesson: Spinoff Of Medical-Surgical Solutions Is A Positive, Strong Buy
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and 63.8% adj. EPS growth, largely driven by strong demand for GLP-1 products, which now represent 12% of total revenue. The company's global supply chain flexibility and non-discretionary drug pricing render it largely immune to tariff uncertainties, ensuring stable future growth.
Read More
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Read More
Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Read More
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
3 Safe Dividend Stocks as Investors Seek to Reset Diversification
Published: April 11, 2025 by: MarketBeat
Sentiment: Positive
Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in technology stocks and even more from the Magnificent 7, the idea of investing in low-growth dividend stocks loses some appeal.
Read More
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns.
Published: April 03, 2025 by: Barrons
Sentiment: Positive
An aging U.S. population is increasing the demand for medication, and this company delivers.
Read More
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.
Read More
McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
McKesson Corporation (NYSE:MCK ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Britt Vitalone – Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst Good morning. Thanks for joining us for the next session here at the TD Cowen Healthcare Conference and very pleased to have with us McKesson.
Read More
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.
Read More
About McKesson Corporation (MCK)
- IPO Date 1994-11-10
- Website https://www.mckesson.com
- Industry Medical - Distribution
- CEO Mr. Brian S. Tyler Ph.D.
- Employees 44000